The inaugural Critical care Research International: Knowledge, Evidence and beYond (CRIKEY) Summit saw more than 80 international delegates come together in Australia for four days of tours, workshops, panel discussions and special events.

Subscribe to CCRG newsletter to learn more about future events.

The first time a conference like this has been held for the critical care community, CRIKEY was designed to be a "Think Tank" for robust conversations and a platform for future research plans and new partnerships. A hope would be that through these partnerships, we can grow and encourage new, young leaders to emerge – from East to West, Rich to Poor. Through their growth, we can ensure the patients of tomorrow will benefit from experts that are borne through such collaborations.

Download programme

The inaugural Critical care Research International: Knowledge, Evidence and beYond brings together the world’s best and brightest ICU researchers for a four-day invitation-only programme of talks, workshops, panel discussions and special events.

Thank you to our industry sponsors

Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. Its products are sold in over 120 countries worldwide. While its early products were designed for use in invasive ventilation, Fisher & Paykel Healthcare has expanded its offering to other clinical applications, including products for non-invasive ventilation, nasal high flow and surgery. The company has a strong history of collaboration with clinicians and supports critical care research projects in a variety of resource settings.
Learn more fphcare.com

Fresenius is a healthcare group offering high-quality products and services for dialysis, hospitals, and outpatient treatment. With over 300,000 employees in more than 100 countries, and annual sales exceeding €37 billion, Fresenius is one of the world’s leading healthcare companies. The Fresenius Group includes four business segments: Fresenius Medical Care is the world leader in treating people with chronic kidney failure. Fresenius Helios is Europe’s largest private hospital operator. Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services to help critically and chronically ill patients, while Fresenius Vamed plans, develops and manages healthcare facilities.

Mallinckrodt Pharmaceuticals is a specialty pharmaceutical company focused on our mission: Managing Complexity. Improving Lives. We provide medicines to address unmet patient needs, stemming from 150 years of using our unique strengths, experience and expertise to help improve people’s lives. Portfolio expansion is a strategic priority for our Science and Technology organization. We are committed to both developing new medicines and generating relevant clinical, health economic and outcomes data that extends the durability of our in-line brands. Mallinckrodt is building on its legacy expertise, especially in formulation technologies and the challenging management of controlled substances, and expanding and deepening our clinical development capabilities.